Tkachev et al. (39) then have shown that in non-human primate models, the combination of KY1005 (OX40L blocking antibody) and sirolimus has synergistic activity in reduction of GVHD mortality associated with control of both Th/Tc1 and Th/Tc17 activity. This evidence concerns the gene TNFSF4 and graft versus host disease.